We are Science Accelerated

We are KCAS Bio, your full-service, global bioanalytical CRO partner with the expertise, capacity and flexibility sponsors require.

How can we help?

Bioanalytical CRO service excellence

We take a consultative approach to our discovery and bioanalytical services, giving our clients' confidence their needs are understood, their objectives will be met, and our promises kept. We consistently benchmark, evaluate and optimize our operations so we can help scientific innovators and investors.

We have supported more than 300+ FDA approved drugs on the market, developed 5,000+ proprietary and non-proprietary assays to date, and undergone 18 FDA audits with no major findings.

Our presence in multiple locations throughout the US and Europe - and with a strategic alliance in Australia - allows us to serve sponsors globally with bioanalytical, biomarker, immunogenicity, cellular and molecular assay services along with clinical kitting and sample management.

Spectral Flow Cytometry on a Global Scale

KCAS Bio is the only bioanalytical laboratory with globally harmonized Cytek spectral flow cytometers, with sites in the US, EU and Australia.

More on Global Spectral Flow Cytometry

400 Years Of Combined Scientific Experience.5000 Proprietary and Non Proprietary Assays Developed to Date.65 PhDs on Staff25 FDA Audits45 Years in Service4 World Wide Locations

Global biomarker and bioanalytical CRO solutions

KCAS Bio is an established bioanalytical CRO with over 40 years' experience. We are very mindful of the human and financial impact of drug development delays. Through our unique approach to capacity planning, we prepare the right expertise with the right capacity and equipment so that we can keep development moving smoothly. Our clients consider us a reliable partner because we strive to minimize downtime, avoid delays, and keep lead times as short as possible.

Explore all our solutions

Find exactly what you’re looking for

Search for specific services, platforms, instrumentation, or scientific insights.

What our clients say

We consistently earn our clients’ trust based on our reputation for transparency, delivering error-free data and keeping our promises.

I want to thank you for yet another great job on a clinical project. From study’s initial contract, to PK kits, to validation and analyses, and ultimately, the final data, all was excellent as always. Happy to work with you all and I look forward to future studies.
VICE PRESIDENT, BIOPHARMACEUTICALS COMPANY
I want to express my appreciation for the professional care and extra effort of the KCAS Bio validation team. It is very evident that these team members truly care about their work and continuously strive towards excellence. I am very grateful to all of them for a thorough review of the document set before, during and after validation. My job of software validation specialist takes me to GLP labs around the world. So, I can say with confidence, that the work done at KCAS Bio was exceptionally well-documented with appropriate detail so anyone could easily understand the steps taken to validate the software.
SOFTWARE VALIDATION SPECIALIST, LAB EQUIPMENT PROVIDER
They developed and validated a pharmacokinetics small molecule method for support of my dog GLP toxicology study. The KCAS Bio work was high quality, on time, within budget, and they had great/open communication.
FOUNDER & CEO, BIOSCIENCE COMPANY
Podcast (The Weekly Bioanalysis) Eps #87: “The Evolution of SCIEX’s Partnership with Pharma in Drug Discovery & Development” Podcasts
Read article Podcast (The Weekly Bioanalysis) Eps #87: “The Evolution of SCIEX’s Partnership with Pharma in Drug Discovery & Development”

In episode 87 of The Weekly Bioanalysis podcast, John Perkins and Dawn Dufield preview the upcoming WRIB conference, where KCAS Bio and Sciex will both have strong representation through scientific presentations, panels, and business development efforts. Special guest, Rahul Baghla of Sciex, discusses the company’s collaboration with KCAS Bio and introduces their…

Key Takeaways from SOT 2025: A Bioanalytical Perspective on the Future of Toxicology Blogs
Read article Key Takeaways from SOT 2025: A Bioanalytical Perspective on the Future of Toxicology

The Society of Toxicology’s SOT 2025 meeting in Orlando, Florida, held from March 20-22, was a unique gathering that highlighted both the ongoing challenges and the evolving opportunities within the toxicology and bioanalytical fields. As a Bioanalytical CRO providing critical dose formulation testing and toxicology studies…

Cutting-Edge PK and Immunogenicity Strategies for Next-Generation ADCs, ARCs, and Conjugated Biotherapeutics Webinars
Read article Cutting-Edge PK and Immunogenicity Strategies for Next-Generation ADCs, ARCs, and Conjugated Biotherapeutics

As the field of biotherapeutics rapidly evolves, the development of advanced conjugated therapies such as Antibody-Drug Conjugates (ADCs), Antibody-RNA Conjugates (ARCs), siRNA/oligos, and antibody-peptide conjugates has gained significant momentum. These next-generation therapeutics offer promising efficacy and safety profiles for treating various conditions, including cancer, rare diseases, and in vaccine development.

Advancing great people and great science

We make nurturing new talent a strategic priority, so that teams are dynamic and constantly improving. We provide a supportive environment for continuous learning and training where you can become your best.

Explore KCAS Bio careers

Scientist Citations

Tell us how we can help with your project

We've earned our reputation for delivering reliable, error-free data. We understand the importance of speed, flexibility, and consistency and only make promises we can keep.

Talk to an expert